Jochen Seufert

Summary

Affiliation: University Hospital
Country: Germany

Publications

  1. ncbi A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus
    Jochen Seufert
    Medizinische Poliklinik, University of Wurzburg, Wuerzburg, Germany
    Clin Ther 26:805-18. 2004
  2. ncbi A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control
    Jochen Seufert
    Division of Endocrinology and Diabetology, University of Freiburg, Freiburg, Germany
    Curr Med Res Opin 22:S39-48. 2006
  3. ncbi 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes
    Jochen Seufert
    Division of Endocrinology and Diabetology, Department of Internal Medicine II, University Hospital of Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany
    Diabetes Res Clin Pract 79:453-60. 2008
  4. ncbi The backbone of oral glucose-lowering therapy: time for a paradigm shift?
    Jochen Seufert
    Division of Endocrinology and Diabetology, University Hospital of Freiburg, Freiburg, Germany
    Fundam Clin Pharmacol 23:651-67. 2009
  5. ncbi [ACCORD (Action to Control Cardiovascular Risk in Diabetes trial) becoming "two-tone"]
    J Seufert
    Schwerpunkt Endokrinologie und Diabetologie, Abteilung Innere Medizin II, , Hugstetter Strasse 55, 79106 Freiburg
    Dtsch Med Wochenschr 133:1068-70. 2008
  6. ncbi Glucose-dependent expansion of pancreatic beta-cells by the protein p8 in vitro and in vivo
    Gunter Path
    Division of Endocrinology and Diabetology, Dept of Internal Medicine II, University Hospital of Freiburg, 79106 Freiburg, Germany
    Am J Physiol Endocrinol Metab 291:E1168-76. 2006
  7. ncbi Analysis of muscle microcirculation in advanced diabetes mellitus by contrast enhanced ultrasound
    D Duerschmied
    Department of Cardiology and Angiology, University Hospital of Freiburg, Hugstetter Street 55, 79106 Freiburg, Germany
    Diabetes Res Clin Pract 81:88-92. 2008
  8. ncbi Diabetic polyneuropathy is associated with respiratory muscle impairment in type 2 diabetes
    H J Kabitz
    Department of Pneumology, University Hospital Freiburg, Killianstrasse 5, 79106, Freiburg, Germany
    Diabetologia 51:191-7. 2008
  9. ncbi [Pharmaceutical therapy of diabetes mellitus type 2]
    K Laubner
    Abteilung Innere Medizin II, Schwerpunkt Endokrinologie und Diabetologie, Universitatsklinikum Freiburg, Freiburg, Deutschland
    Internist (Berl) 48:297-308; quiz 309. 2007
  10. ncbi Leptin effects on pancreatic beta-cell gene expression and function
    Jochen Seufert
    Division of Metabolism, Medizinische Poliklinik, University of Wuerzburg, Wuerzburg, Germany
    Diabetes 53:S152-8. 2004

Collaborators

  • Reinhard G Bretzel
  • H J Kabitz
  • D Duerschmied
  • K Laubner
  • Gunter Path
  • H-J Kabitz
  • P Maletzki
  • C Hehrlein
  • S Kaufmann
  • M Olschewski
  • A Schwoerer
  • F Beuschlein
  • G Freund
  • C Bode
  • F Sonntag
  • D Walker
  • S Walterspacher
  • W Windisch
  • Anita Knoll
  • Veit Rothhammer
  • Anne Opel
  • Martin Gehlen
  • Sigrun Hügl
  • Mathias D Brendel
  • Catarina Limbert
  • Lars Romfeld
  • Xinjie Niu

Detail Information

Publications10

  1. ncbi A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus
    Jochen Seufert
    Medizinische Poliklinik, University of Wurzburg, Wuerzburg, Germany
    Clin Ther 26:805-18. 2004
    ..Although both types of agents improve glycemic control, their mechanisms of action and effects on metabolic processes differ...
  2. ncbi A fixed-dose combination of pioglitazone and metformin: A promising alternative in metabolic control
    Jochen Seufert
    Division of Endocrinology and Diabetology, University of Freiburg, Freiburg, Germany
    Curr Med Res Opin 22:S39-48. 2006
    ..A fixed-dose combination of pioglitazone (a thiazolidinedione) and metformin has been approved for use in the US (Actoplus met) and in Europe (Competact)...
  3. ncbi 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes
    Jochen Seufert
    Division of Endocrinology and Diabetology, Department of Internal Medicine II, University Hospital of Freiburg, Hugstetter Strasse 55, 79106 Freiburg, Germany
    Diabetes Res Clin Pract 79:453-60. 2008
    ..We report the effectiveness of the thiazolidinedione, pioglitazone, as add-on medication to metformin or sulfonylurea in reducing post-load serum glucose levels, as assessed by 3-h oral glucose tolerance testing (OGTT)...
  4. ncbi The backbone of oral glucose-lowering therapy: time for a paradigm shift?
    Jochen Seufert
    Division of Endocrinology and Diabetology, University Hospital of Freiburg, Freiburg, Germany
    Fundam Clin Pharmacol 23:651-67. 2009
    ..A practical approach is taken, reflecting potential clinical situations in which therapeutic intervention is required...
  5. ncbi [ACCORD (Action to Control Cardiovascular Risk in Diabetes trial) becoming "two-tone"]
    J Seufert
    Schwerpunkt Endokrinologie und Diabetologie, Abteilung Innere Medizin II, , Hugstetter Strasse 55, 79106 Freiburg
    Dtsch Med Wochenschr 133:1068-70. 2008
  6. ncbi Glucose-dependent expansion of pancreatic beta-cells by the protein p8 in vitro and in vivo
    Gunter Path
    Division of Endocrinology and Diabetology, Dept of Internal Medicine II, University Hospital of Freiburg, 79106 Freiburg, Germany
    Am J Physiol Endocrinol Metab 291:E1168-76. 2006
    ..These results establish p8 as a novel molecular mediator of glucose-induced pancreatic beta-cell expansion in vitro and in vivo and support the notion of existing beta-cell replication in the adult organism...
  7. ncbi Analysis of muscle microcirculation in advanced diabetes mellitus by contrast enhanced ultrasound
    D Duerschmied
    Department of Cardiology and Angiology, University Hospital of Freiburg, Hugstetter Street 55, 79106 Freiburg, Germany
    Diabetes Res Clin Pract 81:88-92. 2008
    ..However, this approach was not suitable to assess microangiopathy of skeletal muscle, a major contributor to PAD in diabetic patients. We hypothesized that an optimized methodology would detect impaired microcirculation...
  8. ncbi Diabetic polyneuropathy is associated with respiratory muscle impairment in type 2 diabetes
    H J Kabitz
    Department of Pneumology, University Hospital Freiburg, Killianstrasse 5, 79106, Freiburg, Germany
    Diabetologia 51:191-7. 2008
    ..However, data on respiratory neuromuscular involvement in diabetes are lacking. This study therefore aimed to assess respiratory neuromuscular function related to diabetic polyneuropathy in patients with type 2 diabetes...
  9. ncbi [Pharmaceutical therapy of diabetes mellitus type 2]
    K Laubner
    Abteilung Innere Medizin II, Schwerpunkt Endokrinologie und Diabetologie, Universitatsklinikum Freiburg, Freiburg, Deutschland
    Internist (Berl) 48:297-308; quiz 309. 2007
    ..5%, insulin therapy is required either in combination with OADs as a bedtime regimen or as intensive insulin therapy using both basal and short-term acting insulins...
  10. ncbi Leptin effects on pancreatic beta-cell gene expression and function
    Jochen Seufert
    Division of Metabolism, Medizinische Poliklinik, University of Wuerzburg, Wuerzburg, Germany
    Diabetes 53:S152-8. 2004
    ..quot; This leptin resistance at the level of the pancreatic beta-cell may contribute to dysregulation of the adipo-insular axis and promote the development of hyperinsulinemia and manifest type 2 diabetes in overweight patients...